Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Pharmaceuticals Holding Co ( (HK:2607) ) just unveiled an update.
Shanghai Pharmaceuticals Holding Co., Ltd. has released additional information regarding its 2024 annual report, specifically addressing connected transactions and its Share Option Scheme. The company clarified details about ongoing connected transactions with Yunnan Baiyao Group Co., Ltd., Wing Fat Printing Limited, and property leasing agreements with Shanghai Pharma Group. Additionally, the company reported that there were no options available for grant under its Share Option Scheme as of the reporting period, with a total of 680,000 A Shares available for issue, representing a small fraction of the company’s total shares.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$14.00 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
More about Shanghai Pharmaceuticals Holding Co
Shanghai Pharmaceuticals Holding Co., Ltd. is a leading company in the pharmaceutical industry based in China. It is involved in the manufacturing and distribution of pharmaceutical products and medical devices, focusing on both domestic and international markets.
Average Trading Volume: 4,060,084
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$76.68B
Find detailed analytics on 2607 stock on TipRanks’ Stock Analysis page.